Data clean rooms for pharma marketing measurement: A guide to closed-loop ROI

Pharmaceutical and life sciences brands operate with a measurement gap that no other vertical would tolerate. Marketers deploy massive media budgets to reach patients and healthcare providers, yet they have almost no reliable signal connecting that spend to clinical outcomes. The cause of this gap is structural as opposed to operational: Healthcare data cannot leave controlled environments without violating strict privacy laws.

At the same time, the ad platforms will not take in the patient outcome signals that would close the loop, and they keep their own exposure data locked away. Because the patient journey is highly fragmented across digital and physical touchpoints, and treatment decisions now involve a broader care team, pharma brands have historically found it impossible to connect media spend to real-world outcomes.

The structural barriers in pharma marketing measurement

Pharma marketers are trying to solve two distinct but related challenges that require the same secure infrastructure.

First, on the patient side, brands must connect media exposure to real-world outcomes, such as prescription fills or registrations, script lift, audience quality, and healthcare provider visits. This challenge is particularly acute on social media platforms and other walled gardens, where walled gardens lock away exposure data. Historically, marketers relied on tracking pixels to bridge this gap. However, regulatory crackdowns have effectively dismantled this approach. The HHS Office for Civil Rights (OCR) issued guidance on tracking technologies establishing that tracking tools on healthcare websites violate HIPAA if they collect identifiers like IP addresses or device IDs combined with pages containing health-related content. A federal court in AHA v. Becerra vacated this rule for unauthenticated public webpages on June 20, 2024, but tracking on authenticated pages like patient portals remains strictly regulated.

Furthermore, state laws like Washington's My Health My Data Act (WA MHMDA) impose strict consent requirements for collecting and sharing consumer health data, ban geofencing around healthcare facilities, and introduce a private right of action that exposes brands to significant class-action litigation.

These rules carry real teeth. Federal regulators and state class actions have penalized healthcare organizations and digital health platforms for using tracking tools, forcing brands to strip pixels from their sites. That left them blind to campaign performance and reliant on weak proxy metrics like clicks, reach, and impressions.

Second, on the provider side, marketers must understand which touchpoints influence prescribing behavior across a care network that now includes specialists, nurses, pharmacists, and caregivers, rather than just a single physician. According to Definitive Healthcare and industry prescribing data, Nurse Practitioners (NPs) and Physician Associates (PAs) now write more than 25% of all prescriptions in the U.S., making them a critical, often-overlooked segment.

Historically, marketers could not solve either problem because last-touch attribution, cookie-based tracking, and proxy metrics do not connect to clinical outcomes, while HIPAA and state laws make cross-environment sharing legally and technically fraught.

How data clean rooms power healthcare marketing measurement

The emergence of secure data clean rooms offers a neutral infrastructure that solves these challenges. In a data clean room, multiple parties bring their datasets together to run joint analyses, but neither party can see the other's raw records. Only approved, aggregated insights leave the environment.

However, not all clean rooms are created equal. Traditional identity-resolution approaches and policy-based clean rooms rely on contractual trust and software-level administrative policies, such as row-level security, and query templates. During computation, these systems must decrypt data in the system's memory (RAM), meaning the host, cloud provider, or clean room operator can theoretically view the raw data. This is why standard encryption is not enough for highly regulated healthcare data. Furthermore, sharing patient-level data with a social media platform is only lawful under HIPAA when both parties sign a BAA, the contract that governs how two organizations exchange PHI. Major platforms and walled gardens refuse to sign one for their advertising and measurement tools, because they do not want to collect patient outcome signals in the first place. Without that contract, sending them patient data, even hashed or tokenized, is not an option.

This is where confidential computing changes the equation. By using hardware-enforced Trusted Execution Environments (TEEs), confidential computing ensures that data remains encrypted even during active processing. Cryptographic guarantees provide hardware-level protection that prevents unauthorized access, moving beyond mere contractual agreements. This distinction is critical for pharma legal, medical, and regulatory (MLR) teams. Because the system never decrypts the data into a readable format for any human, including the clean room provider, the cloud provider, or the ad platform, it prevents any unauthorized disclosure of raw Protected Health Information (PHI).

Skeptics may argue that setting up hardware-enforced confidential computing clean rooms introduces additional technical complexity, potential performance overhead, and requires specialized engineering knowledge compared to native, zero-copy sharing in a single cloud data warehouse. While this was historically true, modern enterprise SaaS clean rooms have abstracted this complexity into no-code interfaces and standard integrations, allowing teams to deploy enclaves without specialized engineering resources.

By keeping data encrypted during computation, confidential computing enables pharma brands to run analyses without ever exposing raw patient records. With this secure infrastructure, pharma brands can measure real-world outcomes that were previously invisible:

• Script lift and verified prescription fills.
• Healthcare provider visit rates.
• Audience quality and health claim occurrences.

This allows brands to justify their marketing spend. By connecting media spend to clinical outcomes, marketers can replace proxy metrics with hard financial proof.

Closing the social media measurement gap

Social media is one of the hardest channels in healthcare to measure. Platforms will not release their exposure data, and brands cannot upload patient data into them, so the channel stays a blind spot even as more budget moves into it.

This is the gap confidential-computing clean rooms are built to close. Social exposure data and de-identified healthcare data can be brought together inside a secure, hardware-enforced enclave where neither side sees the other's raw records. The analysis runs, and only aggregated results leave the environment. That makes it possible to connect a social media impression to a real-world outcome, such as a prescription fill or a healthcare provider visit, without violating platform terms or HIPAA.

There is a limit worth naming. Because the output is aggregate-only, marketers cannot run granular, patient-level multi-touch attribution (MTA) across non-participating networks. But for brands trying to prove the incrementality of their largest social investments, a secure, aggregate-level lift study is a long way ahead of no measurement at all.

Over time, the same secure model could extend to the provider side of the journey, measuring how marketing influences prescribing across the care team, though this remains an emerging direction rather than a proven capability today.

How outcome-based measurement changes campaign strategy

Transitioning from proxy metrics to real-world outcomes fundamentally changes how pharma brands plan and execute campaigns. Instead of optimizing for clicks or impressions, marketing teams can focus on commercial outcomes:

• Audience quality optimization: Verify whether digital media is successfully reaching the target patient demographic, allowing brands to optimize campaigns based on the quality of the audience reached.
• Channel optimization: Identify which specific channels and publishers actually drive script lift and verified prescription fills, rather than just generating cheap clicks.
• Care-team coordination: Synchronize digital marketing with field force engagement, allowing for timely coordination between sales and marketing. According to Veeva Crossix, timely coordination of reaching a healthcare professional through field reps, marketing, and media leads to a 23% increase in marketing lift.
• Strategic budget allocation: Allocate media budgets based on actual clinical outcomes, and build a bulletproof internal case for media investment to present to the CFO.

To put this into practice, pharma marketers must reconcile the inherent latency of real-world claims data. According to The Tuva Project and industry benchmarks, closed claims can take up to six months to reach full completeness, with an average of 17 weeks to reach 75% completeness. Health plans typically receive only 25% of claims in the actual month of service, and about 55% the following month. Marketers solve this by adopting a dual-speed measurement and optimization framework.

For tactical, in-flight campaign optimization, teams rely on low-latency proxy metrics and predictive baselines. Open claims provide fast signals, with pharmacy claims available within days and medical claims accruing within 21 days to capture over 75% of events. Marketers use early proxy metrics like Audience Quality (AQ) and Doctor Visitation (DV) to verify whether they are reaching the right patient demographics and driving specialist visits, which occur weeks before a prescription is written.

For strategic, long-term return on investment (ROI) measurement and Marketing Mix Modeling (MMM) calibration, marketers apply a runout period of 60 to 90 days and use mathematical projection factors based on historical lag curves to predict final prescription volumes from early, incomplete claims.

The primary risk of a dual-speed framework is the proxy gap. High Audience Quality or Doctor Visitation rates do not always translate to actual script lift or incremental sales. If a campaign successfully reaches the target demographic but the drug's formulary coverage is poor or the physician chooses a competitor, the campaign will fail to drive prescriptions despite positive early indicators. Relying too heavily on weekly predictive baselines can lead to optimization decisions that chase short-term engagement rather than actual clinical outcomes. Marketers must continuously calibrate these proxies against mature claims data to ensure their predictive models remain accurate.

A new standard for closed-loop healthcare measurement

The measurement gap in healthcare marketing is no longer an inevitable cost of doing business. The infrastructure to connect locked-down media exposure to real-world clinical outcomes exists today and supports secure medical data collaboration that facilitates compliance with HIPAA and state privacy laws. By moving beyond administrative policies and adopting hardware-enforced confidential computing, pharma brands can finally prove the clinical and commercial impact of their campaigns.

To learn how Decentriq can help you close the loop on your campaign measurement, visit the Decentriq healthcare solutions page.